AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27608368 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief home-based social work motivational intervention (HSWMI)
Number of subjects: 56
Study 27608368 — intervention group
Group type: COMPARATOR
Intervention: Usual consulting services (Control)
Number of subjects: 56
Study 24332384 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 301
Study 24332384 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 301
Study 24332384 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (open-label extension)
Number of subjects: 301
Study 24332384 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (24-week follow-up)
Number of subjects: 301
Study 21961441 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint therapy plus electrical stimulation
Number of subjects: 68
Study 21961441 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint therapy
Number of subjects: 68
Study 21961441 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 68
Study 20724559 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (inspired PO(2) > 250 Torr)
Number of subjects: 9
Study 19000399 — intervention group
Group type: EXPERIMENTAL
Intervention: Research information sheet for practices, expenses of approximately £3000 per practice, research activity agreements with payment schedule based on deliverables.
Number of subjects: 119
Study 19000399 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 119
Study 16189431 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI planimetry of aortic valve area (MRI‐AVA)
Number of subjects: 33
Study 16189431 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE‐AVA)
Number of subjects: 33
Study 12640257 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II type 1 receptor antagonist)
Number of subjects: 90
Study 12640257 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta1-adrenoceptor antagonist)
Number of subjects: 90
Study 10460983 — intervention group
Group type: EXPERIMENTAL
Intervention: Luffa comp.-Heel nasal spray (0.14 ml per application, 4 times per day)
Number of subjects: 146
Study 10460983 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium spray (control)
Number of subjects: 146
Study 10460983 — intervention group
Group type: EXPERIMENTAL
Intervention: Luffa comp.-Heel nasal spray
Number of subjects: 146
Study 10460983 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium spray
Number of subjects: 146
Study 7754270 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral quantitative computed tomography (pQCT, Densiscan type, thin‐ and multi‐layer technology)
Number of subjects: 70
Study 7754270 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program for identifying women at risk of rapid bone loss
Number of subjects: 70
Study 2491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.0g/m2 days 1 to 4 with mesna uroprotection
Number of subjects: 124
Study 2491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administration of ifosfamide
Number of subjects: 124
Study 2491883 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion schedule of ifosfamide
Number of subjects: 124
Study 2491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance score 0-2 prior to chemotherapy
Number of subjects: 124
Study 2491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance score 0-1 prior to chemotherapy
Number of subjects: 124
Study 2491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotoxicity
Number of subjects: 124
Study 2491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate less than 20
Number of subjects: 124
Study 2491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematuria
Number of subjects: 124
Study 31399883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry syrup formulation (2%, 1g containing 20mg of memantine hydrochloride)
Number of subjects: 0
Study 31399883 — intervention group
Group type: COMPARATOR
Intervention: Film-coated tablet (reference product)
Number of subjects: 0
Study 28117542 — intervention group
Group type: COMPARATOR
Intervention: NORMAL-DUAL
Number of subjects: 58
Study 28117542 — intervention group
Group type: EXPERIMENTAL
Intervention: DUAL-NORMAL
Number of subjects: 58
Study 25185252 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing
Number of subjects: 181
Study 25185252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicanalicular silastic intubation
Number of subjects: 181
Study 24001787 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based website with nurse support
Number of subjects: 31
Study 24001787 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based website alone
Number of subjects: 31
Study 24001787 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based website
Number of subjects: 31
Study 21812265 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal retention enema combined with intrauterine douching
Number of subjects: 131
Study 21812265 — intervention group
Group type: COMPARATOR
Intervention: Direct IVF/ICSI
Number of subjects: 131
Study 20031730 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting TAXUS stent
Number of subjects: 7492
Study 20031730 — intervention group
Group type: COMPARATOR
Intervention: Simple-use cases (single-vessel and single-stent)
Number of subjects: 7492
Study 20031730 — intervention group
Group type: COMPARATOR
Intervention: Expanded use cases
Number of subjects: 7492
Study 20031730 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ST
Number of subjects: 7492
Study 20031730 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ST
Number of subjects: 7492
Study 20031730 — intervention group
Group type: EXPERIMENTAL
Intervention: Very late ST
Number of subjects: 7492
Study 20031730 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with early ST
Number of subjects: 7492
Study 20031730 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with very late ST
Number of subjects: 7492
Study 20031730 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature thienopyridine discontinuation
Number of subjects: 7492
Study 17640415 — intervention group
Group type: EXPERIMENTAL
Intervention: Carob fibre (50 g)
Number of subjects: 19
Study 17640415 — intervention group
Group type: COMPARATOR
Intervention: Control (no carob fibre)
Number of subjects: 19
Study 15173796 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tipped Teflon tracer 0.035-inch guidewire (Group A)
Number of subjects: 400
Study 15173796 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods of cannulation (Group B)
Number of subjects: 400
Study 11716976 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller amplitude visual and somatosensory stimuli co-varied within a trial
Number of subjects: 58
Study 11716976 — intervention group
Group type: COMPARATOR
Intervention: Postural control system with constant weighting of sensory inputs
Number of subjects: 58
Study 10095691 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of medication
Number of subjects: 0
Study 10095691 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-friendly drug leaflets
Number of subjects: 0
Study 7924772 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated pregnant women
Number of subjects: 250
Study 7924772 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnant women
Number of subjects: 250
Study 3094403 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Pressure Ventilation (CPPV)
Number of subjects: 13
Study 3094403 — intervention group
Group type: COMPARATOR
Intervention: High-Frequency Jet Ventilation (HFJV)
Number of subjects: 13
Study 3094403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HFJV with Intermittent Positive Pressure Ventilation (CV)
Number of subjects: 13
Study 30354781 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine therapy
Number of subjects: 2925
Study 26663590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 mcg every 12 h)
Number of subjects: 85
Study 26663590 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (starting from 6 mU/min to maximum 40 mU/min)
Number of subjects: 85
Study 24460033 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% chlorhexidine coating
Number of subjects: 983
Study 24460033 — intervention group
Group type: COMPARATOR
Intervention: Placebo coating
Number of subjects: 983
Study 22979982 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg twice daily) for 4 weeks
Number of subjects: 52
Study 22979982 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) (500 mg once daily) for 4 weeks
Number of subjects: 52
Study 20223132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular anesthesia (8 mL of 2% lidocaine) - Group B
Number of subjects: 160
Study 20223132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clorazepate dipotassium (5 mg one hour before biopsy) - Group C
Number of subjects: 160
Study 20223132 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia and clorazepate - Group D
Number of subjects: 160
Study 20223132 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 160
Study 18672400 — intervention group
Group type: EXPERIMENTAL
Intervention: PBT2 250 mg
Number of subjects: 78
Study 18672400 — intervention group
Group type: EXPERIMENTAL
Intervention: PBT2 50 mg
Number of subjects: 78
Study 18672400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 18389900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily
Number of subjects: 130
Study 18389900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 18389900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily (in patients not receiving stavudine)
Number of subjects: 130
Study 18389900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients not receiving stavudine)
Number of subjects: 130
Study 15364769 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-bowel feeding
Number of subjects: 74
Study 15364769 — intervention group
Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 74
Study 11524351 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 2% lidocaine
Number of subjects: 50
Study 11524351 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mL of 2% lidocaine
Number of subjects: 50
Study 9266230 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1-4 mg o.d.)
Number of subjects: 302
Study 9266230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 8395761 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 6.25 mg orally
Number of subjects: 72
Study 8395761 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 2.5 mg orally
Number of subjects: 72
Study 8395761 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril, 2 mg orally
Number of subjects: 72
Study 8395761 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat, 1.5 mg intravenously
Number of subjects: 72
Study 8395761 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat, 1.0 mg intravenously
Number of subjects: 72
Study 8395761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3531310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. for 6 weeks
Number of subjects: 203
Study 3531310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 31095423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Closed-Loop Control (HCLC)
Number of subjects: 44
Study 31095423 — intervention group
Group type: COMPARATOR
Intervention: Sensor-Augmented Pump (SAP)
Number of subjects: 44
Study 28721310 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual education plus educational DVD
Number of subjects: 37
Study 28721310 — intervention group
Group type: COMPARATOR
Intervention: Usual education
Number of subjects: 37
Study 25461690 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 2031
Study 25461690 — intervention group
Group type: COMPARATOR
Intervention: 24-month DAPT
Number of subjects: 2031
Study 23914733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined VR and upper limb conventional (ULC) therapy
Number of subjects: 376
Study 23914733 — intervention group
Group type: COMPARATOR
Intervention: ULC therapy alone
Number of subjects: 376
Study 21298358 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.4% sodium bicarbonate
Number of subjects: 11
Study 21298358 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium chloride
Number of subjects: 11
Study 19196038 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel electric breast pump (Embrace, Playtex, Westport, CT)
Number of subjects: 62
Study 19196038 — intervention group
Group type: COMPARATOR
Intervention: Standard electric breast pump (Pump In Style, Medela, Baar, Switzerland)
Number of subjects: 62
Study 19196038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pumps
Number of subjects: 62
Study 16952209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen treatment
Number of subjects: 83
Study 16952209 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 83
Study 14610236 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF, filgrastim) 300 microg
Number of subjects: 10
Study 14610236 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg (oral) before G-CSF injection
Number of subjects: 10
Study 14610236 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 11391341 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte colony-stimulating factor (rG‐CSF)
Number of subjects: 155
Study 11391341 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no rG‐CSF)
Number of subjects: 155
Study 11391341 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte colony-stimulating factor (rG‐CSF) in subgroups '<2000 g' or 'neutropenia'
Number of subjects: 155
Study 11391341 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte colony-stimulating factor (rG‐CSF) excluding non-randomized studies
Number of subjects: 155
Study 9257069 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment in comparative cancer trials
Number of subjects: 0
Study 9257069 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival duration
Number of subjects: 0
Study 9257069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient functioning
Number of subjects: 0
Study 9257069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient well-being
Number of subjects: 0
Study 8280188 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E, n = 39)
Number of subjects: 157
Study 8280188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D, n = 40)
Number of subjects: 157
Study 8280188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus Exercise (DE, n = 39)
Number of subjects: 157
Study 8280188 — intervention group
Group type: COMPARATOR
Intervention: Control (C, n = 39)
Number of subjects: 157
Study 2426590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gamma globulin plus aspirin
Number of subjects: 153
Study 2426590 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 153
Study 30451186 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D viewing system
Number of subjects: 50
Study 30451186 — intervention group
Group type: COMPARATOR
Intervention: Conventional microscope
Number of subjects: 50
Study 26926419 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal drug injection
Number of subjects: 62
Study 26926419 — intervention group
Group type: COMPARATOR
Intervention: No multimodal drug injection (control group)
Number of subjects: 62
Study 25144794 — intervention group
Group type: EXPERIMENTAL
Intervention: TB treatment
Number of subjects: 191
Study 22760303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.93 GBq (25 mCi) of iodine-131
Number of subjects: 422
Study 22760303 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.85 GBq (50 mCi) of iodine-131
Number of subjects: 422
Study 22760303 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.7 GBq (100 mCi) of iodine-131
Number of subjects: 422
Study 22760303 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 422
Study 22760303 — intervention group
Group type: COMPARATOR
Intervention: 0.93 GBq (25 mCi)
Number of subjects: 422
Study 22760303 — intervention group
Group type: COMPARATOR
Intervention: 1.85 GBq (50 mCi)
Number of subjects: 422
Study 20649979 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly diluted homeopathic drug (potency C12 = 1024), Dose: 5 globules taken 5 times per day over a maximum period of 5 days
Number of subjects: 30
Study 20649979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose globules)
Number of subjects: 30
Study 18083454 — intervention group
Group type: EXPERIMENTAL
Intervention: Video games promoting health-related behavior change
Number of subjects: 27
Study 18083454 — intervention group
Group type: EXPERIMENTAL
Intervention: Video games with immersive stories and interactivity
Number of subjects: 27
Study 15883353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisection test in severe unilateral neglect group
Number of subjects: 41
Study 15883353 — intervention group
Group type: COMPARATOR
Intervention: Bisection test in group without unilateral neglect
Number of subjects: 41
Study 15883353 — intervention group
Group type: COMPARATOR
Intervention: Bisection test in controls
Number of subjects: 41
Study 15883353 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebisection test in severe unilateral neglect group
Number of subjects: 41
Study 15883353 — intervention group
Group type: COMPARATOR
Intervention: Rebisection test in group without unilateral neglect
Number of subjects: 41
Study 15883353 — intervention group
Group type: COMPARATOR
Intervention: Rebisection test in controls
Number of subjects: 41
Study 12021219 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab in patients with ACS
Number of subjects: 4809
Study 12021219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban in patients without ACS
Number of subjects: 4809
Study 12021219 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban in patients with stable coronary syndromes
Number of subjects: 4809
Study 9857536 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood platelets count, mean blood platelet volume, platelocrit, volume range of blood platelets, coagulation time by Duke's method.
Number of subjects: 45
Study 9857536 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of beta‐thromboglobulin (beta‐TG) and platelet factor‐4 (PF‐4) in plasma by ELISA method.
Number of subjects: 45
Study 9857536 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregation of blood platelets under the influence of ADP according to Born's method.
Number of subjects: 45
Study 9857536 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐TG and PF‐4 standardized based on blood platelets count.
Number of subjects: 45
Study 7826080 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 (KW) 25 mg/m2
Number of subjects: 154
Study 7826080 — intervention group
Group type: COMPARATOR
Intervention: Vindesine (VDS) 3 mg/m2
Number of subjects: 154
Study 7826080 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 (KW) with cisplatin (CDDP) 80 mg/m2
Number of subjects: 154
Study 7826080 — intervention group
Group type: COMPARATOR
Intervention: Vindesine (VDS) with cisplatin (CDDP) 80 mg/m2
Number of subjects: 154
Study 2223417 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg miglitol
Number of subjects: 9
Study 2223417 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acarbose
Number of subjects: 9
Study 2223417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 155096 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 45
Study 155096 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 1.5%
Number of subjects: 45
Study 155096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30659811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 9361
Study 30659811 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 9361
Study 28118174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine therapy (4-8 mg daily, n = 322)
Number of subjects: 645
Study 28118174 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 323)
Number of subjects: 645
Study 26023772 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine using a syringe
Number of subjects: 101
Study 26023772 — intervention group
Group type: COMPARATOR
Intervention: Soapy water using a syringe
Number of subjects: 101
Study 26023772 — intervention group
Group type: COMPARATOR
Intervention: Clear water with soap during a daily shower
Number of subjects: 101
Study 22368214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 22368214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22286574 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-piece acrylic hydrophobic IOL (AcrySof, MA3OBA)
Number of subjects: 96
Study 22286574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece acrylic hydrophobic IOL (AcrySof, SA3OAL)
Number of subjects: 96
Study 22286574 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-piece silicone IOL (CeeOn 911A)
Number of subjects: 96
Study 22286574 — intervention group
Group type: COMPARATOR
Intervention: 3-piece acrylic hydrophobic IOL (AcrySof, MA3OBA) and 1-piece acrylic hydrophobic IOL (AcrySof, SA3OAL)
Number of subjects: 96
Study 22286574 — intervention group
Group type: COMPARATOR
Intervention: All IOL groups
Number of subjects: 96
Study 20191711 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention group
Number of subjects: 18
Study 20191711 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 18
Study 17076980 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 3.8 g/day plus ezetimibe 10 mg/day
Number of subjects: 86